头颈癌放疗期间淋巴细胞与单核细胞比值动态变化的预后意义:大型队列研究结果
该研究回顾性分析了2005至2013年在一家中心接受放疗的1431例头颈癌患者,采用广义估计方程纵向评估放疗期间淋巴细胞与单核细胞比值(LMR)的变化,并将Delta-LMR定义为治疗期间LMR与基线LMR的差值。中位随访9年后,多因素分析显示Delta-LMR是无远处转移生存(FFM)和总生存(OS)的独立预后因素,提示其可能作为简单、廉价的预后生物标志物。
要点
- Delta-LMR定义为放疗期间LMR与基线LMR的差值,是头颈癌放疗患者的独立预后因素。
- 与低Delta-LMR相比,高Delta-LMR患者5年OS和FFM均更差,差异有统计学意义。
- Delta-LMR在放疗2周、4周和6周时均显示与OS和FFM的显著关联。
核心结论
- Delta-LMR是头颈癌放疗患者FFM和OS的独立预后因素,可能作为简单、廉价的临床预后生物标志物。
研究设计与样本
- 回顾性队列研究,纳入2005至2013年在一家中心接受放疗的1431例头颈癌患者,采用广义估计方程纵向评估放疗期间LMR变化。
主要发现
- 中位随访9年,636例(44.4%)患者死亡,240例(16.8%)发生远处转移。
- 放疗2周时高Delta-LMR组与低Delta-LMR组相比,5年OS分别为59%和73%(p < 0.001),5年FFM分别为80%和87%(p = 0.015)。
- 放疗4周时高Delta-LMR组与低Delta-LMR组相比,5年OS分别为60%和72%(p < 0.001),5年FFM分别为79%和86%(p = 0.002)。
- 放疗6周时高Delta-LMR组与低Delta-LMR组相比,5年OS分别为57%和72%(p < 0.001),5年FFM分别为79%和87%(p = 0.002)。
- 多因素分析确定Delta-LMR为FFM和OS的独立预后因素。
临床怎么用
- 在头颈癌放疗过程中动态监测LMR并计算Delta-LMR,可能有助于识别FFM和OS预后较差的患者。
局限性
- 研究为单中心回顾性设计,结论需前瞻性多中心研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: We sought to investigate whether dynamic changes in lymphocyte-to-monocyte ratio (LMR) occurring during the course of radiotherapy (RT) may have prognostic value in patients with head and neck cancer (HNC). MATERIALS AND METHODS: We retrospectively reviewed the clinical records of patients with HNC who underwent RT at our center between 2005 and 2013. Generalized estimating equations were used to longitudinally assess changes in LMR through the course of RT. Delta-LMR was calculated as the difference between LMR measured during treatment and baseline LMR values. Freedom from metastasis (FFM) and overall survival (OS) served as the main outcome measures. RESULTS: A total of 1431 patients with HNC were enrolled. After a median follow-up of 9 years, 636 (44.4%) patients died and 240 (16.8%) had distant metastases. Compared with patients with low delta-LMR at two weeks, those with high delta-LMR experienced less favorable outcomes (five-year OS: 73% versus 59%, respectively, p < 0.001; five-year FFM: 87% versus 80%, respectively, p = 0.015). Similar findings were observed for delta-LMR measured at four weeks (five-year OS: 72% versus 60%, p < 0.001; five-year FFM: 86% versus 79%, respectively, p = 0.002) and six weeks (five-year OS: 72% versus 57%, p < 0.001; five-year FFM: 87% versus 79%, respectively, p = 0.002). Multivariate analysis identified delta-LMR as an independent prognostic factor for both FFM and OS. CONCLUSION: Delta-LMR is a simple and inexpensive biomarker that may be clinically useful for predicting FFM and OS in patients with HNC treated with RT.
引用
- Lin CH, Chou WC, Wu YY, et al. Prognostic significance of dynamic changes in lymphocyte-to-monocyte ratio in patients with head and neck cancer treated with radiotherapy: results from a large cohort study. Radiother Oncol. 2020. PMID: 32941957. doi:10.1016/j.radonc.2020.09.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。